



# mRNA Technology; A Faster Route to Pharmaceutical Therapeutics?

**Aina A\***

School of Engineering, University of Central Lancashire Preston, United Kingdom

**\*Corresponding author:** Adeyinka Aina, School of Engineering, University of Central Lancashire

**Letter to Editor**

**Volume 5 Issue 1**

**Received Date:** January 08, 2021

**Published Date:** February 19, 2021

**DOI:** 10.23880/oajpr-16000224

## Letter to Editor

The COVID-19 pandemic has provided scientists as well as the pharmaceutical industry an exceptional opportunity to perform a feat never seen in the pharmaceutical development process; two novel vaccines were developed within a year and passed regulatory approval for both efficacy and safety.

These vaccines showed efficacies in regions above ninety percent and with almost five million doses administered in the United States of America alone, only twenty-nine allergic

reactions have been reported! (CDC.gov).

All the above was made possible by the usage of what is known as mRNA (messenger Ribonucleic Acid) technology. The thought-provoking question, Dear Editor is, why is this technology not been optimised to find pharmaceutical therapeutics for other diseases most especially cancer? with all the necessary genomic information available for the different forms of cancer?

